hydroxychloroquine has been researched along with Bone Loss, Osteoclastic in 1 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Serum bone resorption marker β-CTx was evaluated in rheumatoid arthritis patients." | 1.48 | Hydroxychloroquine affects bone resorption both in vitro and in vivo. ( Both, T; Lam, WK; Schreuders-Koedam, M; van Daele, PLA; van der Eerden, BCJ; van Hagen, PM; van Leeuwen, JPTM; Vis, M; Weel, AEAM; Zillikens, MC, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Both, T | 1 |
| Zillikens, MC | 1 |
| Schreuders-Koedam, M | 1 |
| Vis, M | 1 |
| Lam, WK | 1 |
| Weel, AEAM | 1 |
| van Leeuwen, JPTM | 1 |
| van Hagen, PM | 1 |
| van der Eerden, BCJ | 1 |
| van Daele, PLA | 1 |
1 other study available for hydroxychloroquine and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Hydroxychloroquine affects bone resorption both in vitro and in vivo.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; C-Reactive Protein; | 2018 |